Multiple Sclerosis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disorder. Although all MS patients initially show a relapsing-remitting course, 20–50% subsequently enter a chronic progressive course at 10–20 years after onset that greatly influences their activities of daily living. There are 2.5 million MS patients worldwide with large regional and racial differences. In particular, there are many MS patients among Caucasians living in Europe, while the disease is relatively rare in Asians and Africans. Although MS is regarded as an autoimmune disease, many factors such as genetic background, environmental factors, and sex are involved in its pathogenesis. While the immunological mechanisms remain to be fully elucidated, invasion of autoreactive T cells into the central nervous system (CNS) tissue is considered the first step of the disease. These T cells react with myelin antigens and initiate demyelination of the CNS by activating cytotoxic T cells, macrophages, and B cells through the release of inflammatory cytokines. As a treatment option, disease-modifying therapies have recently been developed to prevent the recurrence of MS in addition to conventional treatment with corticosteroids for acute relapse. However, there are still few effective treatments for the chronic progressive phase, and it is thus imperative to decipher the mechanism for chronic progression.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer
Pages217-247
Number of pages31
DOIs
Publication statusPublished - Jan 1 2019

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1190
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Multiple Sclerosis
T-cells
Neurology
Demyelinating Diseases
T-Lymphocytes
Macrophages
Central Nervous System
Sex Factors
Recurrence
Nerve Tissue
Adrenal Cortex Hormones
Cells
Therapeutics
Tissue
Activities of Daily Living
Cytokines
Myelin Sheath
Antigens
Autoimmune Diseases
B-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Yamasaki, R., & Kira, J. I. (2019). Multiple Sclerosis. In Advances in Experimental Medicine and Biology (pp. 217-247). (Advances in Experimental Medicine and Biology; Vol. 1190). Springer. https://doi.org/10.1007/978-981-32-9636-7_14

Multiple Sclerosis. / Yamasaki, Ryo; Kira, Jun ichi.

Advances in Experimental Medicine and Biology. Springer, 2019. p. 217-247 (Advances in Experimental Medicine and Biology; Vol. 1190).

Research output: Chapter in Book/Report/Conference proceedingChapter

Yamasaki, R & Kira, JI 2019, Multiple Sclerosis. in Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, vol. 1190, Springer, pp. 217-247. https://doi.org/10.1007/978-981-32-9636-7_14
Yamasaki R, Kira JI. Multiple Sclerosis. In Advances in Experimental Medicine and Biology. Springer. 2019. p. 217-247. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-981-32-9636-7_14
Yamasaki, Ryo ; Kira, Jun ichi. / Multiple Sclerosis. Advances in Experimental Medicine and Biology. Springer, 2019. pp. 217-247 (Advances in Experimental Medicine and Biology).
@inbook{60e84d59059a4109923975e68e730611,
title = "Multiple Sclerosis",
abstract = "Multiple sclerosis (MS) is an inflammatory demyelinating disorder. Although all MS patients initially show a relapsing-remitting course, 20–50{\%} subsequently enter a chronic progressive course at 10–20 years after onset that greatly influences their activities of daily living. There are 2.5 million MS patients worldwide with large regional and racial differences. In particular, there are many MS patients among Caucasians living in Europe, while the disease is relatively rare in Asians and Africans. Although MS is regarded as an autoimmune disease, many factors such as genetic background, environmental factors, and sex are involved in its pathogenesis. While the immunological mechanisms remain to be fully elucidated, invasion of autoreactive T cells into the central nervous system (CNS) tissue is considered the first step of the disease. These T cells react with myelin antigens and initiate demyelination of the CNS by activating cytotoxic T cells, macrophages, and B cells through the release of inflammatory cytokines. As a treatment option, disease-modifying therapies have recently been developed to prevent the recurrence of MS in addition to conventional treatment with corticosteroids for acute relapse. However, there are still few effective treatments for the chronic progressive phase, and it is thus imperative to decipher the mechanism for chronic progression.",
author = "Ryo Yamasaki and Kira, {Jun ichi}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-981-32-9636-7_14",
language = "English",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer",
pages = "217--247",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Multiple Sclerosis

AU - Yamasaki, Ryo

AU - Kira, Jun ichi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Multiple sclerosis (MS) is an inflammatory demyelinating disorder. Although all MS patients initially show a relapsing-remitting course, 20–50% subsequently enter a chronic progressive course at 10–20 years after onset that greatly influences their activities of daily living. There are 2.5 million MS patients worldwide with large regional and racial differences. In particular, there are many MS patients among Caucasians living in Europe, while the disease is relatively rare in Asians and Africans. Although MS is regarded as an autoimmune disease, many factors such as genetic background, environmental factors, and sex are involved in its pathogenesis. While the immunological mechanisms remain to be fully elucidated, invasion of autoreactive T cells into the central nervous system (CNS) tissue is considered the first step of the disease. These T cells react with myelin antigens and initiate demyelination of the CNS by activating cytotoxic T cells, macrophages, and B cells through the release of inflammatory cytokines. As a treatment option, disease-modifying therapies have recently been developed to prevent the recurrence of MS in addition to conventional treatment with corticosteroids for acute relapse. However, there are still few effective treatments for the chronic progressive phase, and it is thus imperative to decipher the mechanism for chronic progression.

AB - Multiple sclerosis (MS) is an inflammatory demyelinating disorder. Although all MS patients initially show a relapsing-remitting course, 20–50% subsequently enter a chronic progressive course at 10–20 years after onset that greatly influences their activities of daily living. There are 2.5 million MS patients worldwide with large regional and racial differences. In particular, there are many MS patients among Caucasians living in Europe, while the disease is relatively rare in Asians and Africans. Although MS is regarded as an autoimmune disease, many factors such as genetic background, environmental factors, and sex are involved in its pathogenesis. While the immunological mechanisms remain to be fully elucidated, invasion of autoreactive T cells into the central nervous system (CNS) tissue is considered the first step of the disease. These T cells react with myelin antigens and initiate demyelination of the CNS by activating cytotoxic T cells, macrophages, and B cells through the release of inflammatory cytokines. As a treatment option, disease-modifying therapies have recently been developed to prevent the recurrence of MS in addition to conventional treatment with corticosteroids for acute relapse. However, there are still few effective treatments for the chronic progressive phase, and it is thus imperative to decipher the mechanism for chronic progression.

UR - http://www.scopus.com/inward/record.url?scp=85075572538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075572538&partnerID=8YFLogxK

U2 - 10.1007/978-981-32-9636-7_14

DO - 10.1007/978-981-32-9636-7_14

M3 - Chapter

C2 - 31760647

AN - SCOPUS:85075572538

T3 - Advances in Experimental Medicine and Biology

SP - 217

EP - 247

BT - Advances in Experimental Medicine and Biology

PB - Springer

ER -